Accepting the uncertainty associated with the positive estimate obtained from pooled data from both pivotal trials, ICER’s revised Evidence Report finds the price range needed to reach standard cost-effectiveness thresholds for Aduhelm is $3,000-$8,400, representing an 85%-95% discount from the announced list price.

At our July 15 public meeting, a roundtable of key stakeholders — including Biogen, the Alzheimer’s Association, and a former FDA and CMS chief — will discuss the mismatch between the announced price and value-based estimates, coverage options for Medicare and private payers, potential research designs for the required confirmatory trial of aducanumab, and the impact of the approval of aducanumab on future development of treatments for Alzheimer’s disease.

Interventions of Interest:

  • aducanumab (Aduhelm™, Biogen)

Date of Review: July 2021

For questions, please contact Laura Cianciolo, Program Manager, at

View the Key Stakeholder List.